Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
Article in Journal for ImmunoTherapy of Cancer (October 2023)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Article in Clinical Cancer Research (October 2022)
Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy
Article in The Cancer Journal (July 2022)